The positive correlation found between elevated expression of the GATA2 gene in clinical metastatic prostate cancers and poor patient prognosis (Fig. 2A–C), as also reported by others [47], indicates that the findings are clinically relevant, and that elevated expression of GATA2 is associated with malignant progression of prostate cancer. This evidence concerns the gene GATA2 and metastatic prostate carcinoma.